Investigational Drug Details
| Drug ID: | D204 |
| Drug Name: | Licogliflozin |
| Synonyms: | LIK-066; LIK066 |
| Type: | Chemical drug |
| DrugBank ID: | DB15048 |
| DrugBank Description: | Licogliflozin is under investigation in clinical trial NCT03320941 (A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity). |
| PubChem ID: | 52913524 |
| CasNo: | 1291094-73-9 |
| Repositioning for NAFLD: | No |
| SMILES: | O[C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)c1cc(Cc2cc3c(cc2)OCCO3)c(cc1)CC |
| Structure: |
|
| InChiKey: | XFJAMQQAAMJFGB-ZQGJOIPISA-N |
| Molecular Weight: | 416.47 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | SGLT1 inhibitor; SGLT2 inhibitor |
| Therapeutic Category: | Improve insulin resistance |
| Clinical Trial Progress: | Phase 2 completed (NCT03205150) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0456 | NCT04065841 | Phase 2 | Recruiting | No Results Available | 19/08/2019 | 21 February 2022 | Details |
| L0999 | EUCTR2019-002324-32-BE | Phase 2 | -- | -- | 2019/12/13 | -- | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |